Eve Montia

USPTO Granted Patents = 11 (Patent Applications = 13)

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 7.8

ph-index = 3

Forward Citations = 19(Granted Patents)

Company Filing History:

Omrix Biopharmaceuticals Inc.

patents

5 out of 60

Compugen Ltd. Corporation

patents

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11986489 - Method of treating a disease using a glycolytic dependent compound (2024-05-21),

2. 11690937 - Antimicrobial compositions comprising minocycline and degradation products of oxidized cellulose (2023-07-04),

3. 11654217 - Antimicrobial compositions comprising minocycline and oxidized cellulose (2023-05-23),

4. 11045588 - Antimicrobial compositions comprising minocycline and degradation products of oxidized cellulose (2021-06-29),

5. 11000635 - Antimicrobial compositions comprising minocycline and oxidized cellulose (2021-05-11),

6. 10960021 - Method of treating a disease using a glycolytic dependent compound (2021-03-30),

7. 10098934 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2018-10-16),

8. 9555087 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2017-01-31),

9. 9375466 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2016-06-28),

10. 9107862 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2015-08-18),

11. 8415455 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics (2013-04-09),

Title: Spotlight on Eve Montia: A Trailblazing Inventor in the Field of Biomedical Innovations

Introduction: Eve Montia, a pioneering inventor hailing from Rehovot, Israel, has made significant contributions to the biomedical field with her groundbreaking patents and innovative research.

Latest Patents: Among Eve Montia's impressive array of 11 patents, two of her recent inventions stand out. The first patent is focused on a method of treating diseases using a glycolytic dependent compound, specifically targeting cancerous tissues by combining oxidized cellulose with the compound. The second patent involves antimicrobial compositions consisting of minocycline and degradation products of oxidized cellulose, showcasing her versatility in developing novel solutions for medical challenges.

Career Highlights: Eve Montia has honed her expertise through roles at esteemed companies such as Omrix Biopharmaceuticals Inc. and Ethicon GmbH. Her tenure at these organizations has been marked by a passion for cutting-edge research and a drive to improve patient outcomes through innovative medical technologies.

Collaborations: Throughout her career, Eve Montia has collaborated closely with accomplished peers in the field. Notably, she has worked alongside talented individuals such as Amir Toporik and Amit Novik, fostering a collaborative spirit that fuels creativity and fosters a culture of innovation.

Conclusion: Eve Montia's inventive spirit and commitment to advancing biomedical solutions have established her as a formidable force in the world of medical innovations. Her groundbreaking patents and successful collaborations underscore her dedication to pushing the boundaries of what is possible in the field of healthcare.

This text is generated by artificial intelligence and may not be accurate.